ArticleJournal of biochemical and molecular toxicology2025
Antagonism of 5-HT7 Receptors as a Promising Target for Gastric Cancer via Apoptotic Pathway.
Article in Journal of biochemical and molecular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Although current treatment strategies have improved clinical outcomes for gastric cancer, they present a challenging prognosis that necessitates novel therapeutic approaches. The 5-HT7 receptor, a member of the serotonin receptor family, plays a significant role in influencing the pathogenesis of various cancer types. This study seeks to investigate the complex interactions among 5-HT7 receptors, gastric cancer, and apoptotic processes. A comprehensive set of experimental techniques was employed, including in vitro staining assays for apoptosis assessment, real-time PCR, and cell proliferation assays. The findings indicate that the 5-HT7 receptor agonist enhances the proliferation of primary gastric tissue cancer cells and KATO-III cells, whereas treatment with the 5-HT7 receptor antagonist significantly inhibits cellular proliferation. Analysis of 5-HT7 receptor mRNA expression in gastric cancer patient populations indicated significantly elevated levels in cancerous tissues when compared to those in healthy tissues. The administration of a 5-HT7 receptor agonist (LP44) resulted in increased cell proliferation in primary gastric cancer cells and KATO-III cell lines, whereas treatment with a 5-HT7 receptor antagonist (SB-269970) significantly inhibited proliferation. Additionally, KATO-III cells treated with the 5-HT7 receptor antagonist demonstrated a marked upregulation of caspase-3, caspase-9, and BAX gene mRNA levels. In contrast, treatment with the 5-HT7 receptor antagonist was associated with a significant reduction in the expression of nuclear factor kappa B and 5-HT7 receptor mRNA levels. Annexin V-FITC/PI and Hoechst 33342 staining demonstrated a pronounced apoptotic effect through antagonism of 5-HT7 receptors compared to other groups. Collectively, the findings of this study suggest that the enhanced expression of 5-HT7 receptors influences gastric cancer formation by regulating the apoptotic axis. This provides a novel perspective for understanding the molecular mechanisms underlying the potential of 5-HT7 receptors as a targeted approach for combating gastric cancer via the apoptotic pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.